Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
ACS Chem Neurosci ; 14(11): 2146-2158, 2023 06 07.
Artigo em Inglês | MEDLINE | ID: mdl-37170554

RESUMO

Cerebral ischemia/reperfusion (I/R) injury is a key reason for the poor prognosis of ischemic stroke. As only a few neuroprotective medications for cerebral I/R injury have been applied in the clinic, it is necessary to design a new therapeutic strategy to treat cerebral I/R injury. The N-salicyloyl tryptamine derivative LZWL02003, synthesized from melatonin and salicylic acid, exhibits a wide range of biological properties. In this study, we assessed the neuroprotective capabilities of LZWL02003 in vivo and in vitro and investigated its possible mechanisms. Oxygen-glucose deprivation/reoxygenation was utilized to create an in vitro model of cerebral I/R damage. Middle cerebral artery occlusion/reperfusion was employed to imitate cerebral I/R injury in vivo. Neuronal apoptosis, oxidative stress, mitochondrial dysfunction, and neuroinflammation are associated with the pathogenesis of cerebral I/R injury. Our findings demonstrated that LZWL02003 upregulated the expression of Bcl-2 and downregulated the expression of Bax, thus maintaining the homeostasis of Bcl-2/Bax proteins and preventing apoptosis. LZWL02003 also reduced oxidative stress by reducing malondialdehyde and reactive oxygen species levels, increasing the superoxide dismutase activity, and resolving mitochondrial malfunction. LZWL02003 can lower interleukin (IL)-1ß, tumor necrosis factor (TNF)-α, and IL-6 levels, which in turn suppress neuroinflammation. Activation of the nuclear factor-kappa B (NF-κB) pathway is involved in various pathophysiologies, including cerebral I/R injury. We discovered that LZWL02003 suppressed the phosphorylation activation of NF-κB pathway-related proteins and decreased the nuclear translocation of NF-κB p65 subunits. Taken together, our results suggest that LZWL02003 is a neuroprotective drug with pleiotropic effects and may be a candidate for treating cerebral I/R injury.


Assuntos
Isquemia Encefálica , Fármacos Neuroprotetores , Traumatismo por Reperfusão , Humanos , NF-kappa B/metabolismo , Fármacos Neuroprotetores/farmacologia , Fármacos Neuroprotetores/uso terapêutico , Proteína X Associada a bcl-2 , Doenças Neuroinflamatórias , Traumatismo por Reperfusão/metabolismo , Isquemia Encefálica/tratamento farmacológico , Infarto da Artéria Cerebral Média/tratamento farmacológico , Proteínas Proto-Oncogênicas c-bcl-2 , Triptaminas/farmacologia , Apoptose
2.
ACS Appl Mater Interfaces ; 14(22): 25490-25500, 2022 Jun 08.
Artigo em Inglês | MEDLINE | ID: mdl-35608938

RESUMO

Nickel-rich layered cathode LiNi0.8Co0.1Mn0.1O2 (NCM811) is the most promising cathode material due to its high specific capacity and lower cost than lithium cobalt oxides. However, NCM811 suffers from structural instability and capacity degradation during charge-discharge cycles. Herein, we report a strategy to construct a conductive network by employing a holistic Ge coating, which interconnects Mg-doped NCM811 particles. Dopant Mg ions, serving as a "pillar" in the Li slab of NCM811, substantially enhance the structural reversibility. The Ge particles are not only coated on the electrode surface but also enter into the electrode pores to form a multidimensional conductive structure, which improves the conductivity of the electrode and slows down the interface side reaction, thus minimizing the irreversible loss of NCM811 upon long cycling. The modified NCM811 electrode delivers a high discharge capacity (∼204 mAh g-1 at 0.1C), excellent rate performance (∼155 mAh g-1 at 10C), and high capacity retention (83% after 200 cycles) even at 4.4 V. Additionally, a cylindrical full battery with graphite/modified NCM811 undergoes 1000 cycles with 86% capacity retention at 2C.

SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa